VarmX

📍 Leiden, Netherlands🗓 Founded 2016👥 29 employees💰 Last funded Mar 2025
Biotechnology Research🌐 varmX.com
Website LinkedIn
VarmX (www.varmx.com) is a young Leiden based biotech company that is focusing on the development of therapies in the field of hemostasis and thrombosis. Originally a spin-off from the Leiden University Medical Center (LUMC), our mission is to develop and manufacture therapeutic proteins to restore hemostasis. Our lead compound, VMX-C001, is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The VarmX program has gained significant interest in the investment community and a very successful Series B financing round of €32 mill. was closed in 2020. This round was followed by a Series B2 round of €32 mill. in May 2023 allowing the company to further progress the lead program towards Investigational New Drug (IND) approval and prepare for pivotal trials.
3
Total investors
0
Early stage
2
Mid stage
1
Late stage
2016
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
3
Investor activity2019–2025 · investors recorded per year
201912020120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in VarmX?
VarmX has 3 investors on record on gritt.io, 2 mid-stage and 1 late-stage investors.
When did VarmX last raise funding?
The most recent investment in VarmX recorded on gritt.io was in March 2025.
When was VarmX founded?
VarmX was founded in 2016.
What industry is VarmX in?
VarmX operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is VarmX based?
VarmX is headquartered in Leiden, Netherlands.